| Literature DB >> 34330280 |
Andreia Marisa Penso Pereira1, Raul Manuel da Silva Laureano2, Fernando Buarque de Lima Neto3.
Abstract
BACKGROUND: The implementation of a population-based screening programme for diabetic retinopathy involves several challenges, often leading to postponements and setbacks at high human and material costs. Thus, it is of the utmost importance to promote the sharing of experiences, successes, and difficulties. However, factors such as the existence of regional programmes, specificities of each country's health systems, organisational and even linguistic barriers, make it difficult to create a solid framework that can be used as a basis for future projects.Entities:
Keywords: Diabetic retinopathy; Population-based screening; Portuguese screenings; Systematic review
Mesh:
Year: 2021 PMID: 34330280 PMCID: PMC8325279 DOI: 10.1186/s12913-021-06776-8
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Fig. 1Flow chart of scientific/technical documents selection process
Quality Criteria Items
| ID | Quality Criteria |
|---|---|
| PQ02 | Are the details of the screening protocol well described? |
| PQ03 | Are the sources reliable? |
| PQ04 | Is the methodology used rigorous and replicable? |
| PQ03 | The geographical area covered and the institution responsible for the screening are well identified? |
| PQ04 | Are the indicators used to measure screening results well described? |
| PQ05 | Does it identify the problems that affect the implementation of population-based screening programs? |
| PQ06 | Does it identify the constraints that affect the implementation of population-based screening programs? |
| PQ07 | Does it identify solutions and best practices from national or international experiences concerning population-based DR screening? |
| PQ08 | Does it objectively describe the evolution of DR screening over a considerably large period? |
Fig. 2DGS Screening Flow Chart. Adapted from [41]
DGS 2018 referral guidelines. Adapted from [40]
| R0 | No disease visible | Repeats screening after a year |
| R1 | Mild No Proliferative DR (NPDR) | Repeats screening after a year |
| R2 | Moderate NPDR | CDTI 1, 2, 3 RD ophthalmologic consultation in a two-month period |
| R3 | Severe NPDR | CDTI 2, 3 RD ophthalmologic consultation in 1 month period |
| Proliferative DR (PDR) | ||
| M1 | Diabetic Macular Edema (DME) | |
| V1 | Hight risk PDR, vitreous haemorrhage, or tractional retinal detachment | CDTI 3 RD ophthalmologic consultation in a 15-day period |
| ICN | Inconclusive or comorbidities | General ophthalmology consultation |
| P0 | Stable LASER | Repeats after a year |
| P1 | Insufficient LASER | CDTI 1 (Thermic LASER) |
DGS 2018 treatment guidelines. Adapted from [40]
| Diabetic retinopathy stage | Procedure and treatment |
|---|---|
| No disease visible or Mild NPDR | DR screening |
| NPDR moderate or severe | DR ophthalmologic consultation Optical coherence tomography (OCT) |
| NPDR with DME focal or multifocal or PDR without DME | Fluorescein angiography (FA) and OCT Laser therapy |
PDR with MDE Diffuse DME | FA + OCT Combined DR therapy: Laser + Intravitreal injection of anti-vascular endothelial growth and/or long-acting corticosteroids |
Advanced PDR with: - Vitreous or sub hyaloid haemorrhage - Retinal detachment - Neovascular glaucoma - Chronic DME with no response to treatment or refractory | DR chirurgic therapy: vitrectomy Combined DR therapy: FA + OCT + Laser + Intravitreal injection of anti-vascular endothelial growth and/or long-acting corticosteroids Corticosteroids extended-release injectable devices |
Screening Protocol
| North | Central | LVT | Alentejo | Algarve | |
|---|---|---|---|---|---|
| Yes | Yes | Yes | Yes | Yes | |
| Yes | Yes | Yes | Yes | Yes | |
| Portable | Portable s | Non-portable - ACES | U | Hospital | |
| No | No | No | No | No | |
| Yes | Yes | Yes | Yes | Yes | |
| Orthoptic technicians provided by hospitals | Orthoptic technicians provided by hospitals | Primary Health Centres orthoptists | U | Hospital Orthoptic technicians | |
| No | Yes | Yes | No | No | |
| Non-mydriatic camera, CR-2 Digital Retinal Camera (Canon) | Nonmydriatic cameras – Canon CR6-45NM with a Sony DXC-950P 3CCD colour video camera | Non-mydriatic camera, CR-2 Digital Retinal Camera (Canon) | U | U | |
| Retinography of both retinal fields, both with 45° field, one focusing on the macula and the other on the optic nerve | Retinography of both retinal fields, both with 45° field, one focusing on the macula and the other on the optic nerve. When impossible to obtain an image with minimum quality is performed an iatrogenic pupil dilation with a topical mydriatic. | Retinography of both retinal fields, both with 45° field, one focusing on the macula and the other on the optic nerve | U | U |
U Unavailable
2015 Results
| North | Central | LVT | Alentejo | Algarve | Total | |
|---|---|---|---|---|---|---|
| 17 | 8 | 11 | 4 | 2 | 42 | |
| 24 | 8 | 15 | 4 | 3 | 54 | |
| 70.8% | 100.0% | 73.3% | 100.0% | 66.7% | 77.8% | |
| 277,706 | 142,008 | 183,958 | 47,221 | U | 674,537 | |
| 75,767 | U | 57,049 | 3501 | 23,404 | 159,721 | |
| 45,119 | 19,792 | 35,602 | 3477 | 16,491 | 120,481 | |
| 3,2% | 3,5% | 3,7% | U | U | U | |
| 59.5% | U | 62.4% | 99.3% | 70.5% | 75.4% | |
| 27.3% | U | 31,0% | 7,4% | U | 23.7% | |
| 16.2% | 13.9% | 19.4% | 7.4% | U | 17.9% |
U Unavailable
2017 Results
| North | Central | LVT | Alentejo | Algarve | |
|---|---|---|---|---|---|
| 75% | 63% | 100% | 50% | 0% | |
| 60% | U | 52% | 91% | NA | |
| 35% | 9% | 29% | 6% | 0 |
U Unavailable, NA Not Applied
Evolution of the number of retinographies
| ARS | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| North | 791 | 8839 | 39,006 | 49,354 | 57,385 | 47,454 | 45,121 | 68,309 | 105,462 |
| Central | 14,760 | 15,271 | 15,258 | 18,496 | 11,856 | 13,235 | 19,792 | U | U |
| LTV | 3131 | 13,867 | 23,221 | 24,819 | 28,272 | 25,853 | 28,562 | 35,602 | 74,744 |
| Alentejo | U | 2761 | 2872 | 2512 | 1668 | 7573 | 3477 | 7144 | 2799 |
| Algarve | 10,907 | 9395 | 13,580 | 7937 | 16,103 | 1420 | 14,491 | U | 0 |
U Unavailable